WVE-003

RNA / oligonucleotide

Weakdesign only

Evidence outlook · no controlled comparison

SELECT-HD (NCT05032196) · Huntington's Disease

The lead study produced no formal comparison against a control: it had a single arm, or its primary endpoint did not compare the groups (for example, a safety count). This tier describes the design, not an outcome.

SELECT-HD (NCT05032196): This was a randomized, double-blind, placebo-controlled study in 47 patients, but its only primary measure was the number of patients with drug-related side effects, so it made no formal test of whether WVE-003 works. Drug-related side effects were seen in 1 of 13, 3 of 10 and 3 of 8 patients at single doses of 30, 60 and 90 mg against 2 of 16 on placebo. Its registered primary outcome on ClinicalTrials.gov is "Safety: Proportion of Patients With Treatment Emergent Adverse Events (TEAEs) Related to Study Drug". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Huntington's Disease

Competitive landscape

2 other tracked programmes target this mechanism, 1 of them ahead of this one.

This drug's own stage for Huntington's Disease: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
WVE-003: this drugPhase 1/2RNA / oligonucleotideHuntingtin (HTT)Weak signal
NCT05032196: Registered primary was the proportion of patients with study-drug-related TEAEs, with no formal test: single doses 30 mg 1/13, 60 mg 3/10, 90 mg 3/8 vs pooled placebo 2/16; multidose 30 mg 8/16 vs placebo 0/7 (CT.gov posted results).
Valbenazine (Ingrezza)ApprovedSmall moleculevesicular monoamine transporter 2 (VMAT2)Partial signal
NCT04102579: Primary endpoint, change in UHDRS Total Maximal Chorea score (average of weeks 10 and 12): -4.6 with valbenazine vs -1.4 with placebo, treatment effect -3.2 units, p<0.0001 (INGREZZA label, KINECT-HD).
VotoplamPhase 3Small moleculeHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
TanruprubartPhase 2Monoclonal antibodyComplement C1qnot yet gradedNo reviewed efficacy summary in this indication
Ifezuntirgene InilparvovecPhase 1/2Gene therapy / editingHuntingtin (HTT) genenot yet gradedNo reviewed efficacy summary in this indication
BrezosiranPhase 1RNA / oligonucleotideHuntingtin (HTT)not yet gradedNo reviewed efficacy summary in this indication
RG6662
—(overall)
Gene therapy / editing—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.